General oxidative stress during doxorubicin-induced cardiotoxicity in rats: Absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid

被引:40
作者
Ghibu, Steliana [2 ]
Delemasure, Stephanie [1 ]
Richard, Carole [1 ]
Guilland, Jean-Claude [1 ]
Martin, Laurent [3 ]
Gambert, Segolene [4 ]
Rochette, Luc [1 ]
Vergely, Catherine [1 ]
机构
[1] Univ Bourgogne, Lab Physiopathol & Pharmacol Cardiovasc Expt, IFR Sante STIC 100, Fac Med & Pharm, F-21000 Dijon, France
[2] Univ Med & Pharm, Fac Pharm, Dept Pharmacol Physiol & Physiopathol, Cluj Napoca, Romania
[3] Ctr Hosp Univ, Dept Pathol, F-21000 Dijon, France
[4] Ctr Hosp Univ, Dept Biochem, F-21000 Dijon, France
关键词
Doxorubicin; Alpha-lipoic acid; Rat hearts; Oxidative stress; Cardioprotection; Anthracyclines; ANTHRACYCLINE-INDUCED CARDIOTOXICITY; SYMPTOMATIC DIABETIC POLYNEUROPATHY; INDUCED CARDIOMYOPATHY; HEART-FAILURE; DEXRAZOXANE; EXPRESSION; CHILDREN; APOPTOSIS; TOXICITY; ADHESION;
D O I
10.1016/j.biochi.2011.02.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To evaluate the effects of alpha-lipoic acid (AL) in a model of doxorubicin (DOX)-induced cardiotoxicity, male Wistar rats were treated with DOX (1 mg/kg/d; 10 d) in combination or not with AL (50 mg/kg/d; 15 d). Plasma oxidative stress was determined by hydroperoxides (ROOH) and the ascorbyl radical/ascorbate ratio. One and two months later, the functional parameters of the hearts were determined in vivo by catheterization and cardiac oxidative stress was assessed by malonedialdehyde (MDA) and O-2(center dot-) (dihydroethidium fluorescence) content in tissue. After two months, body weight was higher in the DOX-AL group than in DOX (+16%), but this was due to ascites. Histological liver alterations were observed in both the DOX and DOX-AL groups. Plasma ROOH concentrations decreased after 10 days of AL treatment, but were greater in both the DOX and DOX-AL groups. After two months, a decrease in the cardiac contractility index (-27% and -29%, respectively) and cardiac hypertrophy were observed in DOX and DOX-AL These dysfunctions were associated with I) a reduction in plasma ascorbate levels and an increase in the ascorbyl/ascorbate ratio and 2) an increase MDA and O-2(center dot-) content in cardiac tissue. In conclusion, a cumulative dose of 10 mg/kg doxorubicin induced functional alterations in the heart associated with plasma and cardiac oxidative stress. The co-administration of the antioxidant compound AL had no beneficial effects in this situation. (C) 2011 Published by Elsevier Masson SAS.
引用
收藏
页码:932 / 939
页数:8
相关论文
共 49 条
[1]   Alpha-lipoic acid ameliorates myocardial toxicity induced by doxorubicin [J].
Al-Majed, AA ;
Gado, AM ;
Al-Shabanah, OA ;
Mansour, MA .
PHARMACOLOGICAL RESEARCH, 2002, 46 (06) :499-503
[2]   Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients [J].
Anderson, B .
PEDIATRIC BLOOD & CANCER, 2005, 44 (07) :584-588
[3]  
Bennink RJ, 2004, J NUCL MED, V45, P842
[4]   The pharmacology of the antioxidant lipoic acid [J].
Biewenga, GP ;
Haenen, GRMM ;
Bast, A .
GENERAL PHARMACOLOGY, 1997, 29 (03) :315-331
[5]  
Bilska A, 2005, PHARMACOL REP, V57, P570
[6]   Pro-oxidant actions of α-lipoic acid and dihydrolipoic acid [J].
Çakatay, U .
MEDICAL HYPOTHESES, 2006, 66 (01) :110-117
[7]   α-lipoic acid decreases thiol reactivity of the insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes [J].
Cho, KJ ;
Moini, H ;
Shon, HK ;
Chung, AS ;
Packer, L .
BIOCHEMICAL PHARMACOLOGY, 2003, 66 (05) :849-858
[8]   Reactive oxygen species function as second messenger during ischemic preconditioning of heart [J].
Das, DK ;
Maulik, N ;
Sato, M ;
Ray, PS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1999, 196 (1-2) :59-67
[9]   Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review [J].
De Beer, EL ;
Bottone, AE ;
Voest, EE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 415 (01) :1-11
[10]  
Delemasure S., 2006, Annales de Cardiologie et d'Angeiologie, V55, P104, DOI 10.1016/j.ancard.2006.02.005